Calls Now Open

2024 ADDF-Harrington + 2025 Harrington Scholar-Innovator Programs

You've just added:

December 05, 2023

An Enzyme that Selectively S-nitrosylates Proteins to Regulate Insulin Signaling

Researchers at Case Western Reserve University and University Hospitals have identified an enzyme that blocks insulin produced in the body—a discovery that could provide a new target to treat diabetes.

Their study, published Dec. 5 in the journal Cell, focuses on nitric oxide, a compound that dilates blood vessels, improves memory, fights infection and stimulates the release of hormones, among other functions. How nitric oxide performs these activities had long been a mystery.

Highlights

  • SCAN catalyzes protein S-nitrosylation using S-nitroso-CoA as a cofactor
  • S-nitrosylation of insulin receptor and IRS1 by SCAN regulates insulin signaling
  • Hypernitrosylation of INSR and IRS1 by SCAN causes diabetes
  • SCAN expression correlates with human BMI and INSR S-nitrosylation

Summary

Acyl-coenzyme A (acyl-CoA) species are cofactors for numerous enzymes that acylate thousands of proteins. Here, we describe an enzyme that uses S-nitroso-CoA (SNO-CoA) as its cofactor to S-nitrosylate multiple proteins (SNO-CoA-assisted nitrosylase, SCAN). Separate domains in SCAN mediate SNO-CoA and substrate binding, allowing SCAN to selectively catalyze SNO transfer from SNO-CoA to SCAN to multiple protein targets, including the insulin receptor (INSR) and insulin receptor substrate 1 (IRS1). Insulin-stimulated S-nitrosylation of INSR/IRS1 by SCAN reduces insulin signaling physiologically, whereas increased SCAN activity in obesity causes INSR/IRS1 hypernitrosylation and insulin resistance. SCAN-deficient mice are thus protected from diabetes. In human skeletal muscle and adipose tissue, SCAN expression increases with body mass index and correlates with INSR S-nitrosylation. S-nitrosylation by SCAN/SNO-CoA thus defines a new enzyme class, a unique mode of receptor tyrosine kinase regulation, and a revised paradigm for NO function in physiology and disease.

Learn More

About the Scholar

Jonathan Stamler

Cardiovascular

Jonathan Stamler, MD

University Hospitals - Cleveland
Harrington Investigators

More about Jonathan Stamler

We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.